-
Goldman Initiates Impax Labs With Sell Rating, $33 Target
Monday, June 6, 2016 - 11:46am | 322Read More...Although Impax Laboratories Inc (NASDAQ: IPXL)'s prospects have improved since the remediation of its manufacturing issues in 2015, Goldman Sachs’ Stephan Stewart believes “the fundamental outlook is fully reflected in the stock,” and there could be “increased competition...
-
IBM Teams Up With Pfizer To Move Towards Parkinson's Cure
Thursday, April 7, 2016 - 1:47pm | 336Read More...International Business Machines Corp. (NYSE: IBM) and Pfizer Inc. (NYSE: PFE) announced on Thursday a collaboration to develop monitoring solutions aimed at transforming how health care providers deliver care to patients suffering from Parkinson's disease. According to IBM's press...
-
Acadia Continues Huge Rise Following FDA Panel Vote
Wednesday, March 30, 2016 - 7:52am | 177Read More...Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) were trading higher by more than 22 percent early Wednesday morning. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease,...
